Patents by Inventor Richland Wayne Tester

Richland Wayne Tester has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 11351168
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: June 7, 2022
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 11292772
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: April 5, 2022
    Assignee: Celgene CAR LLC
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20210017137
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Application
    Filed: February 21, 2020
    Publication date: January 21, 2021
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 10828300
    Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 10, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 10596172
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 24, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 10570099
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 25, 2020
    Assignee: Celgene CAR LLC
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190192512
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 29, 2018
    Publication date: June 27, 2019
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20190152925
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 23, 2019
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190117650
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 25, 2019
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 10010548
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: July 3, 2018
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 10005738
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Celgene CAR LLC
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 9987276
    Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 5, 2018
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20170217904
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 3, 2017
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20170100397
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 27, 2016
    Publication date: April 13, 2017
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20170095475
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 12, 2016
    Publication date: April 6, 2017
    Inventors: Richland Wayne Tester, Prasoon Chaturvedi, Zhendong Zhu, Sekhar S. Surapaneni, Lisa Beebe
  • Besylate salt of a BTK inhibitor
    Patent number: 9604936
    Abstract: The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: March 28, 2017
    Assignee: Celgene CAR LLC
    Inventors: Steven Richard Witowski, William Frederick Westlin, III, Richland Wayne Tester
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 9540335
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: January 10, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160311780
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 12, 2016
    Publication date: October 27, 2016
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland Wayne Tester
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160303121
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 24, 2016
    Publication date: October 20, 2016
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, Deqiang Niu, Lixin Qiao
  • 2,4-disubstituted pyrimidines as kinase inhibitors
    Patent number: 9409921
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: August 9, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao